High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial

• Status: Completed
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

High-Dose Vitamin D3 in the Treatment of Human Immune Deficiency Virus Patients, A Double-Blind Randomized Control Trial Human immunodeficiency virus is a key challenge for global health. Vitamin D deficiency is common in people living with HIV infection. Antiretroviral therapy may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of the Punjab
• Collaborator: The National HIV/AIDS Programme
• Treatments: Calcifediol; Hydroxycholecalciferols

Criteria

Inclusion Criteria:

1. Age from 19 years and above

2. Vitamin-D levels less than 20ng/ml

3. Not taking any kind of Vitamin-D supplementation or Mega Doses for last six months

4. Written Informed Consent Form

5. PCR Positive Patients

Exclusion Criteria:

1. Pregnant and Lactating Women

2. Ability to take Study Medication Orally